Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of Rinatabart Sesutecan versus investigator's choice in platinum-resistant ovarian cancer
CTR20253987Phase 3Active
- Sponsor
- ProfoundBio
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rinatabart sesutecan in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by ProfoundBio. Started Dec 2025; status: active.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20253987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253987.